The research objectives were to: 1) determine differences in BPSD based on clinical AD status (i.e., cognitively stable, MCI, and dementia); and 2) examine the association between neuroimaging biomarkers of early AD pathology (i.e., Aβ PET and tau PET) and BPSD in individuals with DS. The gene discussed is MAPT; the disease is dementia.